earnings
confidence high
sentiment neutral
materiality 0.60
Enliven Therapeutics Q2 net loss $20.0M; cash $312.4M; pipeline advances with ELVN-001/002 dosing starts
Enliven Therapeutics, Inc.
2024-Q2 EPS reported
-$0.95
- Cash, cash equivalents and marketable securities of $312.4M as of June 30, 2024, expected to fund operations into late 2026.
- Q2 2024 net loss $20.0M ($16.7M Q2 2023); R&D expense $18.8M ($15.2M), G&A $5.8M ($5.0M).
- ELVN-001 Phase 1b arm dosing initiated in CML patients; abstract accepted for September ESH-iCMLf conference.
- ELVN-002 Phase 1a combo trial with trastuzumab +/- chemo and exploratory arm with Kadcyla dosed first patients.
- Phase 1 data for ELVN-001 and initial ELVN-002 combo data expected in 2025.